Devyser Diagnostics AB (publ) (DVYSR) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the Devizor Q1 2025 earnings call. I'm Fredrik Thalen, the acting CEO of Devizor and would like to thank you everyone for joining our call today. On the call today we have in addition to myself also our CFO Sabina Berlin and our Chief Commercial Officer Thijs Kipling. I will start with a short summary of our quarterly results and then recap our updated strategy and present some highlights from the team before handing over to Sabina for more detailed review of our financial results in Q1 2025 and then to Thijs for an update on our commercial activities. We had another solid quarter based on revenue, the second strongest quarter in the history of the company. The revenue was 55 million SEK representing a growth of 8% compared to Q1 last year. Gross margins were 83% and EBIT minus 21 million SEK. including 8 million SEC in one-offs related to reorg and another 6 million SEC in FX headwinds. Our cash position was 114 million SEC. As mentioned on the previous call, we have made some updates on our strategy that we now have started to execute on. The overall goal for us in the coming year is to make Divisor a more efficient organization, and that goal starts with a clear and more focused strategy. As mentioned, we propose focusing on two customer segments, the clinical genetic labs and the transplantation laboratories. We strongly believe there are significantly more unmet diagnostic needs that we can address here, together with our customers and scientific collaborators. We are now in the process of updating our product roadmap by reaching out to our top customers and asking them what they need help with. This voice of customer exercise will guide us to better prioritize which products we should develop in the coming years. Transplantation diagnost...